期刊
HEPATOLOGY RESEARCH
卷 47, 期 10, 页码 1053-1060出版社
WILEY
DOI: 10.1111/hepr.12844
关键词
bone metastasis; HCC; serum NTX; skeletal-related event; zoledronic acid
AimsWe retrospectively analyzed the clinical outcome and prognostic parameters in patients with hepatocellular carcinoma (HCC) and bone metastases who had received treatment with zoledronic acid (ZOL). MethodsNinety-nine HCC patients with bone metastases who had been treated with ZOL were enrolled in this retrospective cohort study. We analyzed the prognostic factors, including serum N-telopeptide of type I collagen (NTX) levels, as bone metabolism markers. ResultsThe median overall survival (OS) time was 11.5months. Child-Pugh grade A (P=0.004) and intrahepatic tumor stage (IHTS) T0-3 (P=0.010) correlated significantly with favorable OS. In 46 patients with grade A and T0-3, receiver operating characteristic curve analysis defined 16nmolBCE/L serum NTX as the cut-off level for median OS. Multivariate analysis identified baseline serum NTX <16nmolBCE/L (P=0.045) as the only significant and independent determinant of OS. ConclusionLow baseline serum NTX level correlated with favorable outcome in bone metastatic HCC patients with Child-Pugh grade A and IHTS T0-3 treated with ZOL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据